학술논문
Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis
Document Type
article
Author
Lage, Ricardo da Cruz; Marques, Claudia Diniz Lopes; Oliveira, Thauana Luiza; Resende, Gustavo Gomes; Kohem, Charles Lubianca; Saad, Carla Gonçalves; Ximenes, Antônio Carlos; Gonçalves, Célio Roberto; Bianchi, Washington Alves; Meirelles, Eduardo de Souza; Keiserman, Mauro Waldemar; Chiereghin, Adriano; Campanholo, Cristiano Barbosa; Lyrio, André Marun; Schainberg, Cláudia Goldenstein; Pieruccetti, Lenise Brandao; Yazbek, Michel Alexandre; Palominos, Penelope Esther; Goncalves, Rafaela Silva Guimarães; Assad, Rodrigo Luppino; Bonfiglioli, Rubens; Lima, Sônia Maria Alvarenga Anti Loduca; Carneiro, Sueli; Azevedo, Valderílio Feijó; Albuquerque, Cleandro Pires; Bernardo, Wanderley Marques; Sampaio-Barros, Percival Degrava; Pinheiro, Marcelo de Medeiros
Source
Advances in Rheumatology. January 2021 61
Subject
Language
English
ISSN
2523-3106
Abstract
Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians’ decision making, without taking out his/her autonomy when prescribing for an individual patient.